Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Opa-Locka, Florida Clinical Trials

A listing of Opa-Locka, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (1166) clinical trials

If you’re taking High Cholesterol medication, you may qualify for a research study. Investigational medication provided at no charge Study-related care from a local doctor at no charge

Phase N/A

3.27 miles

Learn More »

This phase 2 study is a multicenter, exploratory study designed to evaluate the efficiency and safety of Febuxostat 40 mg in subjects with Gout and moderate renal impairment.

Phase

3.27 miles

Learn More »

Mechanisms and Treatment Response of Aggressive Periodontitis in Children

There a multiple appointments throughout the study which can vary depending upon if a patient has the disease present or not. If the patient has gum disease: At the initial examination, some samples will be collected: the natural fluid that comes from the gums and the bacteria that are present ...

Phase N/A

3.27 miles

Learn More »

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Healthy infants will be enrolled and randomized to receive either 4 doses of MenACYW conjugate vaccine or 4 doses of the licensed control vaccine, MENVEO. All participants will receive routine vaccines as per the Advisory Committee on Immunization Practices (ACIP) recommendations. All participants will be assessed for immunogenicity at baseline ...

Phase

3.27 miles

Learn More »

A Trial to Evaluate the Safety Efficacy and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

This is a phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose trial designed to assess the efficacy, safety, and tolerability of brexpiprazole compared with placebo. The trial consists of a 12-week double-blind treatment period with a 30 day follow-up. The trial population will include male and female subjects between 55 ...

Phase

3.27 miles

Learn More »

Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis

The primary objective of this study is to assess the efficacy and safety of two doses of vilaprisan compared to placebo in women with symptomatic endometriosis. The secondary objective of this study is to evaluate the safety and tolerability of two different doses of vilaprisan in women with symptomatic endometriosis.

Phase

3.27 miles

Learn More »

Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)

This is an open-label study to evaluate the safety of continued therapy with oral treprostinil in subjects who have completed Study TDE-HF-301. This study will provide long-term, open-label data regarding the effect of continued long-term oral treprostinil therapy for the treatment of pulmonary hypertension (PH) associated with heart failure with ...

Phase

3.39 miles

Learn More »

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test in patients with chronic HF with reduced ejection fraction (LVEF 40%) Secondary objectives are to assess Patient-Reported Outcome (PRO)

Phase

3.39 miles

Learn More »

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Subjects will be enrolled in Groups 1 through 4 as follows: Group 1: Approximately 6 to 8 male and female subjects with moderate hepatic impairment (with a Child-Pugh score of 7 to 9) will be enrolled in Group 1. Group 2: Approximately 6 to 8 healthy male and female subjects ...

Phase

3.43 miles

Learn More »

RSV Investigational Vaccine in RSV-seropositive Infants Aged 12 to 23 Months

The RSV PED-002 study, designed to evaluate the safety, reactogenicity and immunogenicity of the RSV candidate vaccine when administered in 3 sequential doses to seropositive infants aged 12 to 23 months, will be conducted in an observer-blind manner in Epoch 1 and single-blinded in Epoch 2.

Phase

3.43 miles

Learn More »